Reports Q4 revenue GBP 8.05B, consensus GBP 7.66B. Emma Walmsley, Chief Executive Officer, GSK, said: “GSK delivered excellent performance in 2023, with clear highlights being the exceptional launch of Arexvy and continued progress in our pipeline. We are now planning for at least 12 major launches from 2025, with new Vaccines and Specialty Medicines for infectious diseases, HIV, respiratory and oncology. As a result of this progress and momentum, we expect to deliver another year of meaningful sales and earnings growth in 2024, and we are upgrading our growth outlooks for 2026 and 2031. We remain focused on delivering this potential – and more – to prevent and change the course of disease for millions of people.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GSK:
- Lixte Biotechnology announces first patient dosed in Phase 1b/2 trial of LB-100
- GSK RSV vaccine accepted for regulatory review by EMA for adults 50-59
- GSK Earnings this Week: How Will it Perform?
- Guggenheim ups CymaBay price target to $28, sees M&A potential
- M & A News: Suave Brands Acquires Haleon’s (NYSE:HLN) ChapStick in $510M Deal
